These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31249480)

  • 1. Refractory Insomnia in an Adolescent with Total Blindness.
    Tubbs AS; Grandner MA; Combs D
    Yale J Biol Med; 2019 Jun; 92(2):201-204. PubMed ID: 31249480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tasimelteon for the treatment of non-24-hour sleep-wake disorder.
    Neubauer DN
    Drugs Today (Barc); 2015 Jan; 51(1):29-35. PubMed ID: 25685859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
    Stahl SM
    CNS Spectr; 2014 Dec; 19(6):475-8. PubMed ID: 25422900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
    Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
    Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.
    Keating GM
    CNS Drugs; 2016 May; 30(5):461-8. PubMed ID: 27003694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tasimelteon for treating non-24-h sleep-wake rhythm disorder.
    Nishimon S; Nishimon M; Nishino S
    Expert Opin Pharmacother; 2019 Jun; 20(9):1065-1073. PubMed ID: 30990759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tasimelteon approved for circadian disorder in blind adults.
    Traynor K
    Am J Health Syst Pharm; 2014 Mar; 71(5):350. PubMed ID: 24534583
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnosis and Treatment of Non-24-h Sleep-Wake Disorder in the Blind.
    Emens JS; Eastman CI
    Drugs; 2017 Apr; 77(6):637-650. PubMed ID: 28229310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
    Leger D; Quera-Salva MA; Vecchierini MF; Ogrizek P; Perry CA; Dressman MA
    Expert Opin Drug Saf; 2015; 14(11):1673-85. PubMed ID: 26393492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder.
    Med Lett Drugs Ther; 2014 Apr; 56(1441):34-5. PubMed ID: 24759294
    [No Abstract]   [Full Text] [Related]  

  • 11. Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.
    Bonacci JM; Venci JV; Gandhi MA
    J Pharm Pract; 2015 Oct; 28(5):473-8. PubMed ID: 25092604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.
    Hardeland R
    Curr Opin Investig Drugs; 2009 Jul; 10(7):691-701. PubMed ID: 19579175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tasimelteon: first global approval.
    Dhillon S; Clarke M
    Drugs; 2014 Mar; 74(4):505-11. PubMed ID: 24610704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entraining the free-running circadian clocks of blind people.
    Eastman C
    Lancet; 2015 Oct; 386(10005):1713. PubMed ID: 26554081
    [No Abstract]   [Full Text] [Related]  

  • 15. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.
    Johnsa JD; Neville MW
    Ann Pharmacother; 2014 Dec; 48(12):1636-41. PubMed ID: 25204464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-24-Hour Sleep-Wake Rhythm Disorder in Sighted and Blind Patients.
    Uchiyama M; Lockley SW
    Sleep Med Clin; 2015 Dec; 10(4):495-516. PubMed ID: 26568125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tasimelteon for insomnia.
    Lankford DA
    Expert Opin Investig Drugs; 2011 Jul; 20(7):987-93. PubMed ID: 21548834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.
    Rajaratnam SM; Polymeropoulos MH; Fisher DM; Roth T; Scott C; Birznieks G; Klerman EB
    Lancet; 2009 Feb; 373(9662):482-91. PubMed ID: 19054552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment.
    Torres R; Kramer WG; Baroldi P
    J Clin Pharmacol; 2015 May; 55(5):525-33. PubMed ID: 25450415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe restless legs syndrome presenting as intractable insomnia.
    Arnulf I; Konofal E; Gauthier C; Chedru F
    Neurology; 2004 Apr; 62(8):E19. PubMed ID: 15111708
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.